Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor
Bioorganic & Medicinal Chemistry Letters · 2025
DOI: 10.1016/j.bmcl.2025.130262 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2025. Verfasst von Scott Throner und 19 weiteren Autor:innen. Beteiligte Einrichtung: Tango Therapeutics, 201 Brookline Ave, Boston, MA 02215, United States. Hauptthemen laut MEDLINE: Ubiquitin-Specific Proteases, Drug Discovery, Antineoplastic Agents, Protease Inhibitors. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
USP1 (ubiquitin-specific peptidase 1) is a deubiquitinating enzyme that has been identified as essential in BRCA1/2 mutant cells and implicated in the DNA damage response. Inhibition of USP1 by small molecule inhibitors disrupts DNA repair and replication and is being pursued as a potential anticancer therapeutic in BRCA1/2 mutant cancers. We report the discovery of an in vitro and in vivo USP1 inhibitor tool compound TNG-6132 (18), a reversible, allosteric inhibitor of USP1, which strongly inhibits USP1 enzymatic activity. This inhibitory effect translates into in vitro cellular viability defects in a BRCA1-mutant breast cancer cell line, as well as an in vivo pharmacodynamic (PD) response and tumor growth suppression in a mouse xenograft efficacy model. Additionally, we report an X-ray co-crystal structure of TNG-6132 (18) bound in the USP1-UAF1 complex, a result that furthered our understanding of the role played by key elements of the pharmacophore of this chemotype as well as its mechanism of inhibition of USP1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tango Therapeutics, 201 Brookline Ave, Boston, MA 02215, United States.
Zitieren
APA
Throner, S., Feng, T., Andersen, J. N., Bandi, M., Engel, J. L., Gong, S., Gotur, D., Gu, L., Huang, A., Lazarides, K., Maxwell, J. P., McCarren, P., McMillan, B. J., Pham, T. V., Simoneau, A., Tsai, A., Whittington, D. A., Wilker, E., Zhang, M., & Zhang, W. (2025). Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2025.130262
Vancouver
Throner S, Feng T, Andersen JN, Bandi M, Engel JL, Gong S, et al. Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor. Bioorganic & Medicinal Chemistry Letters. 2025. doi:10.1016/j.bmcl.2025.130262
BibTeX
@article{Throner2025,
author = {Throner, Scott and Feng, Tianshu and Andersen, Jannik N and Bandi, Madhavi and Engel, Justin L and Gong, Shanzhong and Gotur, Deepali and Gu, Lina and Huang, Alan and Lazarides, Katherine and Maxwell, John P and McCarren, Patrick and McMillan, Brian J and Pham, Truc V and Simoneau, Antoine and Tsai, Alice and Whittington, Douglas A and Wilker, Erik and Zhang, Minjie and Zhang, Wenhai},
title = {Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2025},
doi = {10.1016/j.bmcl.2025.130262}
}
EUVIMED